Trial Profile
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADEPT
- Sponsors Abbott Laboratories
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 03 Jan 2019 Results of a post-hoc anaysis assessing the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab or placebo and the impact of concomitant MTX, published in the Rheumatology
- 08 Nov 2017 Results of post-hoc analysis (n=296) assessing the relationship between inhibition of radiographic progression and disease activity in Adalimumab and placebo treated patients presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.